CA3113226A1 - Antibacterial compounds - Google Patents
Antibacterial compounds Download PDFInfo
- Publication number
- CA3113226A1 CA3113226A1 CA3113226A CA3113226A CA3113226A1 CA 3113226 A1 CA3113226 A1 CA 3113226A1 CA 3113226 A CA3113226 A CA 3113226A CA 3113226 A CA3113226 A CA 3113226A CA 3113226 A1 CA3113226 A1 CA 3113226A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- prodrug
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734173P | 2018-09-20 | 2018-09-20 | |
| US62/734,173 | 2018-09-20 | ||
| US201862767313P | 2018-11-14 | 2018-11-14 | |
| US62/767,313 | 2018-11-14 | ||
| PCT/US2019/052021 WO2020061375A1 (en) | 2018-09-20 | 2019-09-19 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113226A1 true CA3113226A1 (en) | 2020-03-26 |
Family
ID=69887856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113226A Pending CA3113226A1 (en) | 2018-09-20 | 2019-09-19 | Antibacterial compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11407740B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3853210A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7495395B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102954539B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166077B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019345150A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021005044A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3113226A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281614B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021003084A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202102712WA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI900469B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020061375A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
| EP3621962A4 (en) | 2017-05-10 | 2020-12-09 | Forge Therapeutics, Inc. | ANTIBACTERIAL COMPOUNDS |
| WO2020061375A1 (en) | 2018-09-20 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
| EP4700030A3 (en) | 2019-11-14 | 2026-03-18 | Amgen, Inc. | Improved synthesis of kras g12c inhibitor compound |
| WO2021195260A1 (en) * | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
| WO2021195258A1 (en) * | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor, formulations, and uses thereof |
| WO2023011573A1 (zh) * | 2021-08-05 | 2023-02-09 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
| WO2023011574A1 (zh) * | 2021-08-05 | 2023-02-09 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
| AR127139A1 (es) * | 2021-09-28 | 2023-12-20 | Forge Therapeutics Inc | Inhibidores de lpxc y usos de estos |
| EP4568955A4 (en) * | 2022-08-10 | 2026-08-12 | Blacksmith Medicines Inc | ANTIBACTERIAL COMPOUNDS |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK273689A (da) * | 1988-06-06 | 1989-12-07 | Sanofi Sa | 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US5543534A (en) | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| US6875619B2 (en) | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
| US20050009101A1 (en) | 2001-05-17 | 2005-01-13 | Motorola, Inc. | Microfluidic devices comprising biochannels |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| AR037641A1 (es) | 2001-12-05 | 2004-11-17 | Tularik Inc | Moduladores de inflamacion |
| CN1688291A (zh) | 2002-02-01 | 2005-10-26 | 辉瑞产品公司 | 含有固体药物分散体的即刻释放剂型 |
| ES2387803T3 (es) | 2003-01-08 | 2012-10-02 | Novartis Vaccines And Diagnostics, Inc. | Agentes antibacterianos |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| WO2006028523A2 (en) | 2004-04-29 | 2006-03-16 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| DE102004021779A1 (de) * | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CN101528711A (zh) | 2006-08-31 | 2009-09-09 | 先灵公司 | 可用作抗细菌剂的乙内酰脲衍生物 |
| EA200970349A1 (ru) | 2006-10-05 | 2010-02-26 | Янссен Фармацевтика Н.В. | Ингибиторы металлопротеазы гетероциклического происхождения |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| US8871728B2 (en) * | 2007-06-29 | 2014-10-28 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| IT1392249B1 (it) | 2008-11-28 | 2012-02-22 | Univ Degli Studi Urbino | Derivati di [(3-idrossi-4-piron-2-il)metil]-amina e loro uso come farmaci anti-neoplastici |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| WO2012151567A1 (en) * | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| WO2012177635A1 (en) | 2011-06-19 | 2012-12-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| EP2847174B1 (en) | 2012-04-03 | 2017-05-17 | Bristol-Myers Squibb Company | Pyrimidinone carboxamides as inhibitors of endothelial lipase |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| HK1211289A1 (en) * | 2012-08-06 | 2016-05-20 | Savira Pharmaceuticals Gmbh | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| AU2014209107B2 (en) | 2013-01-28 | 2018-04-12 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| WO2014160649A1 (en) * | 2013-03-29 | 2014-10-02 | Novartis Ag | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections |
| AU2014306451B2 (en) * | 2013-08-16 | 2019-01-17 | Duke University | Substituted hydroxamic acid compounds |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| US9988373B2 (en) | 2013-12-26 | 2018-06-05 | Shionogi & Co., Ltd. | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same |
| CA2960949A1 (en) | 2014-09-12 | 2016-03-17 | Tatsuya Honda | Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof |
| HUE047225T2 (hu) | 2014-12-16 | 2020-04-28 | Novartis Ag | LpxC inhibitor izoxazol hidroxámsav-vegyületek |
| CN105777464B (zh) | 2014-12-26 | 2020-09-29 | 中国科学院上海药物研究所 | 异羟肟酸衍生物及其制备方法和应用 |
| US10611747B2 (en) | 2015-11-09 | 2020-04-07 | Forge Therapeutics, Inc. | Pyrone based compounds for treating bacterial infections |
| EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
| EP3190103A1 (en) * | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| US10889556B2 (en) | 2016-03-08 | 2021-01-12 | The Regents Of The University Of California | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease |
| US11034650B2 (en) * | 2016-12-23 | 2021-06-15 | Intervet Inc. | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection |
| US20200062789A1 (en) | 2017-01-31 | 2020-02-27 | Fujifilm Toyama Chemical Co., Ltd. | Hydroxamic acid prodrug compound or salt thereof, lyophilized formulation, lpxc inhibitor, and antibacterial agent |
| EP3621962A4 (en) | 2017-05-10 | 2020-12-09 | Forge Therapeutics, Inc. | ANTIBACTERIAL COMPOUNDS |
| WO2018208987A2 (en) | 2017-05-10 | 2018-11-15 | Forge Therapeutics, Inc. | Antibacterial compounds |
| WO2018216822A1 (en) | 2017-05-25 | 2018-11-29 | Taisho Pharmaceutical Co., Ltd. | Novel imidazole derivatives |
| WO2019086452A1 (en) * | 2017-10-31 | 2019-05-09 | Idorsia Pharmaceuticals Ltd | Antibacterial heteroaromatic compounds |
| KR102868718B1 (ko) | 2018-02-10 | 2025-10-14 | 케이비피 바이오사이언시즈 씨오., 엘티디. | 항생제로서 작용하는 화합물 |
| WO2020061375A1 (en) | 2018-09-20 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
| US20220081421A1 (en) | 2018-11-14 | 2022-03-17 | Forge Therapeutics, Inc. | Antibacterial compounds |
| WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
| WO2021195258A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor, formulations, and uses thereof |
| WO2022086920A1 (en) | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
| AR124839A1 (es) | 2021-02-11 | 2023-05-10 | Forge Therapeutics Inc | Compuestos antibacterianos |
| EP4291550A4 (en) * | 2021-02-11 | 2025-01-22 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| AR127139A1 (es) * | 2021-09-28 | 2023-12-20 | Forge Therapeutics Inc | Inhibidores de lpxc y usos de estos |
| EP4568955A4 (en) | 2022-08-10 | 2026-08-12 | Blacksmith Medicines Inc | ANTIBACTERIAL COMPOUNDS |
| WO2024036170A1 (en) | 2022-08-10 | 2024-02-15 | Blacksmith Medicines, Inc. | Antibacterial compounds |
-
2019
- 2019-09-19 WO PCT/US2019/052021 patent/WO2020061375A1/en not_active Ceased
- 2019-09-19 BR BR112021005044-2A patent/BR112021005044A2/pt not_active Application Discontinuation
- 2019-09-19 EP EP19862323.3A patent/EP3853210A4/en active Pending
- 2019-09-19 KR KR1020217011553A patent/KR102954539B1/ko active Active
- 2019-09-19 SG SG11202102712WA patent/SG11202102712WA/en unknown
- 2019-09-19 JP JP2021514980A patent/JP7495395B2/ja active Active
- 2019-09-19 CN CN201980076710.3A patent/CN113166077B/zh active Active
- 2019-09-19 CA CA3113226A patent/CA3113226A1/en active Pending
- 2019-09-19 IL IL281614A patent/IL281614B2/en unknown
- 2019-09-19 MX MX2021003084A patent/MX2021003084A/es unknown
- 2019-09-19 AU AU2019345150A patent/AU2019345150A1/en not_active Abandoned
- 2019-09-20 TW TW108134051A patent/TWI900469B/zh active
-
2021
- 2021-03-18 US US17/205,750 patent/US11407740B2/en active Active
-
2022
- 2022-06-09 US US17/836,255 patent/US12325699B2/en active Active
-
2025
- 2025-04-30 US US19/194,662 patent/US20260001869A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210070308A (ko) | 2021-06-14 |
| IL281614B2 (en) | 2024-12-01 |
| IL281614B1 (en) | 2024-08-01 |
| TWI900469B (zh) | 2025-10-11 |
| SG11202102712WA (en) | 2021-04-29 |
| CN113166077B (zh) | 2025-01-28 |
| MX2021003084A (es) | 2021-08-11 |
| AU2019345150A1 (en) | 2021-05-13 |
| EP3853210A1 (en) | 2021-07-28 |
| WO2020061375A1 (en) | 2020-03-26 |
| TW202023561A (zh) | 2020-07-01 |
| JP2022502362A (ja) | 2022-01-11 |
| KR102954539B1 (ko) | 2026-04-17 |
| US20220324846A1 (en) | 2022-10-13 |
| US20260001869A1 (en) | 2026-01-01 |
| BR112021005044A2 (pt) | 2021-06-08 |
| US20210221796A1 (en) | 2021-07-22 |
| IL281614A (en) | 2021-05-31 |
| US11407740B2 (en) | 2022-08-09 |
| US12325699B2 (en) | 2025-06-10 |
| JP7495395B2 (ja) | 2024-06-04 |
| WO2020061375A8 (en) | 2021-03-11 |
| EP3853210A4 (en) | 2022-06-22 |
| CN113166077A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7495395B2 (ja) | 抗菌性化合物 | |
| WO2018208987A2 (en) | Antibacterial compounds | |
| US11021471B2 (en) | Antibacterial compounds | |
| WO2018015818A2 (en) | Therapeutic inhibitory compounds | |
| EP4175642A1 (en) | Compounds, compositions and methods | |
| AU2019237991A1 (en) | JAK inhibitors | |
| WO2025137267A1 (en) | Modulators of tnf-alpha activity | |
| CN120303261A (zh) | 苯并螺环吲哚化合物的制备、应用及用途 | |
| CN110981882B (zh) | 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途 | |
| WO2018075871A1 (en) | Novel antibiotics and methods of using same | |
| EA045324B1 (ru) | Антибактериальные соединения | |
| WO2015184405A1 (en) | Aromatic compounds, compositions and uses thereof | |
| CN113801135B (zh) | 噻吩并吡唑类化合物,包含其的药物组合物及其用途 | |
| EP4727943A1 (en) | Inhibitors of met kinase | |
| WO2026064273A1 (en) | Inhibitors of tnf alpha activity | |
| WO2025231273A1 (en) | Antibacterial compounds | |
| HK40042878A (en) | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| HK40042878B (en) | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| HK40037094B (en) | Amino acid compounds and methods of use | |
| HK40037094A (en) | Amino acid compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240910 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260306 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260506 |